Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 6/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | BCR | P11274 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670448 | 0.87 | FAAH (0.40) | FAAHFGFR4CSNK1DCSNK1E | |
| SCHEMBL17624235 | 0.87 | FAAH (0.40) | FAAHFGFR4CSNK1DCSNK1E | |
| SCHEMBL17618373 | 0.87 | FAAH (0.40) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL19365762 | 0.87 | FAAH (0.40) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL16775963 | 0.86 | FAAH (0.42) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL19670312 | 0.86 | KDR (0.39) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL17618367 | 0.85 | FAAH (0.41) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL19706218 | 0.85 | FAAH (0.41) | FAAHKDRFGFR4MAPK14TNNI3K | |
| SCHEMBL17624593 | 0.84 | TRPV1 (0.40) | — | |
| SCHEMBL19670310 | 0.83 | FAAH (0.38) | FAAHKDRFGFR4MAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083386-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 1092/4885KDR 1526/4885FGFR4 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.